Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma

• Published in: Endocrine-related cancer Vol. 16; no. 3; pp. 919 - 928
• Main Authors: Fenske, Wiebke, Völker, Hans-Ullrich, Adam, Patrick, Hahner, Stefanie, Johanssen, Sarah, Wortmann, Sebastian, Schmidt, Melanie, Morcos, Michael, Müller-Hermelink, Hans-Konrad, Allolio, Bruno, Fassnacht, Martin
• Format: Journal Article
• Language: English
• Published: England Society for Endocrinology 01.09.2009; BioScientifica
• Subjects: Adrenal Cortex Neoplasms - diagnosis; Adrenal Cortex Neoplasms - metabolism; Adrenal Cortex Neoplasms - pathology; Adrenocortical Carcinoma - diagnosis; Adrenocortical Carcinoma - metabolism; Adrenocortical Carcinoma - pathology; Adult; Aged; Biomarkers, Tumor - metabolism; Biomarkers, Tumor - physiology; Female; Glucose - metabolism; Glucose Transporter Type 1 - metabolism; Glucose Transporter Type 1 - physiology; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Regular papers
• ISSN: 1351-0088; 1479-6821
• DOI: 10.1677/ERC-08-0211

Owing to the rarity of adrenocortical carcinoma (ACC) no prognostic markers have been established beyond stage and resection status. Accelerated glycolysis is a characteristic feature of cancer cells and in a variety of tumour entities key factors in glucose metabolism like glucose transporter 1 and 3 (GLUT1 and -3), transketolase like-1 enzyme (TKTL1) and pyruvate kinase type M2 (M2-PK) are overexpressed and of prognostic value. Therefore, we investigated the role of these factors in ACC. Immunohistochemical analysis was performed on tissue microarrays of paraffin-embedded tissue samples from 167 ACCs, 15 adrenal adenomas and 4 normal adrenal glands. Expression was correlated with baseline parameters and clinical outcome. GLUT1 and -3 were expressed in 33 and 17% of ACC samples respectively, but in none of the benign tumours or normal adrenals glands. By contrast, TKTL1 and M2-PK were detectable in all benign tissues and the vast majority of ACCs. GLUT1 expression was strongly associated with prognosis in univariate and multivariate analysis (P<0.01), whereas GLUT3, TKTL1 and M2-PK did not correlate with clinical outcome. Patients with strong GLUT1 staining showed a considerably higher overall mortality (hazard ratio (HR) 6.34 (95% confidence interval 3.10–12.90) compared with patients with no GLUT1 staining. When analysing patients in their early stages and advanced disease separately, similar results were obtained. HR for survival was 5.31 (1.80–15.62) in patients with metatastic ACC and in patients after radical resection the HR for disease-free survival was 6.10 (2.16–16.94). In conclusion, GLUT1 is a highly promising stage-independent, prognostic marker in ACC.